Scores in Animal Study; Confirmed Photographic Findings

WEST HAVEN, Conn.–(EMWNews)–NanoViricides, Inc. (OTC BB: NNVC.OB)

(the “Company”)

reported today that excellent efficacy of its EKC-Cide™

nanoviricide drug candidate was revealed upon statistical analyses of

clinical scores from the first animal study.

The EKC-Cide drug candidate clearly demonstrated prevention of

conjunctival injection (redness, dilation and prominence of the

conjunctival blood vessels) and blepharitis (crusting, discharge and

inflammation of the eyelid margins) using mathematical clinical scores

calculations. These data confirmed the excellent clinical response

observed earlier in eye photographs. In contrast, the control group

which received an inactive drop preparation (“negative

control”) displayed statistically significant

higher clinical scores consistent with the expected strong progression

of infection.

A rapid clinical response to the EKC-Cide treatment was also revealed by

these data, confirming earlier photograph observations. Substantial

differences in clinical scores, demonstrating clear prevention of

serious infection and improvement upon treatment, were observed within

three days after treatment. Moreover, while both scored parameters

(conjunctivitis and blepharitis) were still significantly elevated even

at day 10 in the “negative control”

group; in the EKC-Cide treated group both parameters had returned to

normal already at day 7, indicating full recovery.

These clinical scores were based on daily observations and recording of

the animals by trained observers. Further biological analyses are in

progress.

“These results confirm our earlier preliminary

photographic evidence,” said Eugene Seymour,

MD, MPH, CEO of the Company, adding, “We now

know that EKC-Cide efficacy is substantially superior to that of other

drugs in development against EKC.”

The Company has previously posted

photos on its website which demonstrated the rapid response to

treatment using the Company’s nanoviricide

drug candidate against Epidemic Kerato-Conjunctivitis (EKC) (http://www.nanoviricides.com/action_small_EKC_2008-06-09.html).

“EKC-Cide may have efficacy against other

viral conjunctivitis as well,” said Anil R.

Diwan, Ph.D., President of the Company, “It

uses a broad-spectrum ligand for finding the virus. Binding sites for

this ligand may be present on a large number of viruses.”

The Company plans to evaluate this broad-spectrum eye-drop formulation

against other viruses that cause eye diseases such as herpes simplex

virus (HSV).

The Company has previously reported that it is in talks with certain

pharmaceutical companies regarding potential licensing of a nanoviricide

against adenoviral EKC.

The two clinical scores employed were for “conjunctival

injection” i.e. redness and dilation or

prominence of conjunctival blood vessels, and for “blepharitis”

i.e. crusting, discharge and inflammation of eyelid margins. Both are

classic signs of pathological infection.

While the Company currently has no approved product for the treatment of

EKC and viral conjunctivitis, the treatment and prophylaxis market for

these classes of eye disease is expected to be of the order of several

billion dollars annually.

EKC is a highly contagious and very severe inflammation of the eyes that

results in disabling red eyes, discharge and inflammation of the eyelids

with clinical symptoms lasting several weeks. Bacterial conjunctivitis

may be treated with antibiotics; however, there is no treatment

currently available for viral EKC. Further, viral EKC, in some cases,

may result in the formation of hazy spots in the cornea called “sub-epithelial

infiltrates” which cause blurriness of

vision, a condition that may last up to two years.

About NanoViricides:

NanoViricides, Inc. (www.nanoviricides.com)

is a development stage company that is creating special purpose

nanomaterials for viral therapy. The Company’s novel nanoviricide™

class of drug candidates are designed to specifically attack enveloped

virus particles and to dismantle them. The Company is developing drugs

against a number of viral diseases including H5N1 bird flu, seasonal

influenza, HIV, EKC, hepatitis C, rabies, dengue fever, and Ebola virus,

among others.

This press release contains forward-looking statements that reflect the

Company’s current expectation regarding future events. Forward-looking

statements involve risks and uncertainties. Actual events could differ

materially and substantially from those projected herein and depend on a

number of factors. Certain statements in this release, and other written

or oral statements made by NanoViricides, Inc. are “forward-looking

statements” within the meaning of Section 27A

of the Securities Act of 1933 and Section 21E of the Securities Exchange

Act of 1934. These forward looking statements are subject to known and

unknown risks, uncertainties and other factors that may cause actual

results, performance, or achievements of the company to be different

from those expressed or implied including the success of the Company’s

research and development efforts, the availability of adequate

financing, the successful and timely completion of clinical studies and

the uncertainties related to the regulatory process, described in the “Management’s

Discussion and Analysis” section of the

Company’s Form 10-KSB and other reports and

filings with the Securities and Exchange Commission.

Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89

Get Unlimited Organic Website Traffic to your Website 
TheNFG.com now offers Organic Lead Generation & Traffic Solutions